Chardan Capital Raises SAB Biotherapeutics (NASDAQ:SABS) Price Target to $16.00
Chardan Capital raised its price target for SAB Biotherapeutics (NASDAQ:SABS) to $16.00 from $14.00 and reiterated a “buy” rating, according to a Wednesday research note cited by Benzinga. The target implies 337.16% upside versus the stock’s current price. Other firms’ targets ranged from $10 to $12, while one reiterated a “sell (d+)”.
How this was made
The 30-second read
Why it matters
A higher price target can attract incremental speculative interest, but the article’s only new fact is the PT revision; it does not introduce new trial results, approvals, or guidance.
Market read
Traders may use the PT change as a sentiment input, but the lack of new operational catalysts keeps expected impact limited.
What to watch
Other analysts are still mixed (e.g., Weiss “sell (d+)” and Zacks downgrade to “hold”), suggesting the PT dispersion could cap upside and increase volatility.
Background
The piece summarizes a sell-side research note from Chardan Capital and lists other recent rating/target changes, plus basic trading and financial metrics and the last reported earnings date.
Ticker impact
Chardan Capital raised its SAB Biotherapeutics price target from $14 to $16 and reiterated a “buy,” implying large upside from the current price.
Likely modest, sentiment-driven upside bias; follow-through depends on whether other analysts revise estimates after the target change.
The article discloses a fresh, attributable PT change (Chardan) and reiterates buy, but provides no new clinical, regulatory, or financial datapoint beyond previously reported earnings context.
Market effects
Reinforces bullish sell-side sentiment toward clinical-stage antibody platforms, but without new trial/regulatory specifics it’s unlikely to re-rate the whole biotech group.
No clear regional spillover; impact is primarily single-name sentiment.
Limited global relevance; no international deal/regulatory action mentioned.
Counterpoint
The stock’s fundamentals remain weak (negative P/E, recent EPS miss), so PT hikes may not translate into sustained price action without new efficacy/safety or financing updates.
Key entities
- companySAB Biotherapeutics
Clinical-stage biotech developing fully human polyclonal antibody therapeutics; subject of the analyst price-target change.
- research_firmChardan Capital
Raised its SAB Biotherapeutics price target from $14 to $16 and maintained a “buy” rating.
